Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement

Clinical Immunology

Volumn 148, Issue 2, 2013, Pages 177-185

  Sethu, Swaminathan ^a   Govindappa, Karthik ^a   Quinn, Paul ^a   Wadhwa, Meenu ^b   Stebbings, Richard ^b   Boggild, Mike ^c,d   Naisbitt, Dean ^a   Kimber, Ian ^a,e   Pirmohamed, Munir ^a   Park, Kevin ^a   Sathish, Jean ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^d TOWNSVILLE HOSPITAL   (Australia)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anti drug antibody; ; Complement; Immunogenicity; ; Interferon beta; ; Neutralising antibody; Relapsing remitting multiple sclerosis;

Indexed keywords

BETA1A INTERFERON; DRUG ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BIOASSAY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ANTI-DRUG ANTIBODY;; COMPLEMENT; IMMUNOGENICITY;; INTERFERON BETA;; NEUTRALISING ANTIBODY;; RELAPSING-REMITTING MULTIPLE SCLEROSIS;;

ADULT; COMPLEMENT ACTIVATION; CROSS REACTIONS; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; YOUNG ADULT;

EID: 84879336715     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.05.008     Document Type: Article

References (28)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
2. Li D.K., Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann. Neurol. 1999, 46:197-206.
3. Paty D.W., Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:662-667.
4. Perini P., Calabrese M., Biasi G., Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J. Neurol. 2004, 251:305-309.
5. Sorensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005, 65:33-39.
6. Strayer D.R., Carter W.A. Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J. Interferon Cytokine Res. 2012, 32:95-102.
7. Baudouin V., Crusiaux A., Haddad E., Schandene L., Goldman M., Loirat C., Abramowicz D. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003, 76:459-463.
8. Bennett C.L., Luminari S., Nissenson A.R., Tallman M.S., Klinge S.A., McWilliams N., McKoy J.M., Kim B., Lyons E.A., Trifilio S.M., Raisch D.W., Evens A.M., Kuzel T.M., Schumock G.T., Belknap S.M., Locatelli F., Rossert J., Casadevall N. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 2004, 351:1403-1408.
9. Bertolotto A., Gilli F., Sala A., Capobianco M., Malucchi S., Milano E., Melis F., Marnetto F., Lindberg R.L., Bottero R., Di Sapio A., Giordana M.T. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003, 60:634-639.
10. Chirmule N., Jawa V., Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012, 14:296-302.
11. Deisenhammer F., Reindl M., Berger T. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b. J. Interferon Cytokine Res. 2001, 21:167-171.
12. Gibbs E., Oger J. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J. Neuroimmunol. 2007, 190:146-150.
13. Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 2004, 5:981-986.
14. Strainic M.G., Liu J., Huang D., An F., Lalli P.N., Muqim N., Shapiro V.S., Dubyak G.R., Heeger P.S., Medof M.E. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008, 28:425-435.
15. Weaver D.J., Reis E.S., Pandey M.K., Kohl G., Harris N., Gerard C., Kohl J. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur. J. Immunol. 2010, 40:710-721.
16. Pachner A.R., Dail D., Pak E., Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J. Neuroimmunol. 2005, 166:180-188.
17. Farina C., Vargas V., Heydari N., Kumpfel T., Meinl E., Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J. Neuroimmunol. 2002, 123:188-192.
18. Basile E., Gibbs E., Aziz T., Oger J. During 3years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J. Neuroimmunol. 2006, 177:161-166.
19. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., Kuter D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
20. Bertolotto A., Malucchi S., Milano E., Castello A., Capobianco M., Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000, 48:95-100.
21. Khan O.A., Dhib-Jalbut S.S. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998, 51:1698-1702.
22. Sominanda A., Lundkvist M., Fogdell-Hahn A., Hemmer B., Hartung H.P., Hillert J., Menge T., Kieseier B.C. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Arch. Neurol. 2010, 67:1095-1101.
23. Shapiro A.M., Jack C.S., Lapierre Y., Arbour N., Bar-Or A., Antel J.P. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system. Arch. Neurol. 2006, 63:1296-1299.
24. Hegen H., Schleiser M., Gneiss C., Di Pauli F., Ehling R., Kuenz B., Lutterotti A., Berger T., Deisenhammer F. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult. Scler. 2012, 18:610-615.
25. O'Garra A., Vieira P. Regulatory T cells and mechanisms of immune system control. Nat. Med. 2004, 10:801-805.
26. Minagara A., Murray T.J., Investigators P.S. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. Curr. Med. Res. Opin. 2008, 24:1049-1055.
27. Ingram G., Hakobyan S., Hirst C.L., Harris C.L., Loveless S., Mitchell J.P., Pickersgill T.P., Robertson N.P., Morgan B.P. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult. Scler. 2012, 18:1401-1411.
28. Boos L., Campbell I.L., Ames R., Wetsel R.A., Barnum S.R. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J. Immunol. 2004, 173:4708-4714.